|
 |
| |
| |
| |
| At the advanced edge of oncology, rapid access to accurate data on disease state is vital. The fully automated Idylla™ system, in combination with the Idylla™ Mutation Assays (tissue and liquid biopsy), is the future of diagnosis and monitoring. |
|
|
|
| |
| |
|
|
|
|
|
| |
| Colorectal, lung and melanoma |
| |
|
| |
| “The Idylla™ System has the potential to allow the start of targeted therapy within a time window of less than 24 hours following the diagnosis of metastasis by analysing tumor or ctDNA, thereby saving precious time”. |
| |
| Prof.B.Neyns, M.D.,Ph.D. - Medical Oncology, UZ Brussels, Belgium |
| |
|
|
|
| |
 |
| |
| Would you like to experience this breakthrough technology? |
| |
| Visit us at ESMO, 07 Oct - 11 Oct 2016, booth #428 or click below to request a personal demo. |
| |
|
|
| |
|
|
| |
| Would you like to learn more about the Idylla™ System and Assays in Oncology? |
| |
| Visit our website, just drop us an email to seeing-is-believing@biocartis.com or click below to download brochures. |
| |
|
|
| |
|
|
|
| |
 |
| |
|
Biocartis, Generaal de Wittelaan 11B3, B-2800, Belgium. Phone: +32 15 632 600 www.biocartis.com
|
|
| |
| |
|
Biocartis trademark and logo are trademarks belonging to Biocartis and are used and registered in Europe. Idylla™ is a registered trademark in the United States and other countries. Idylla™ trademark and logo are used trademarks belonging to Biocartis. Idylla™ platform is a CE-marked IVD in Europe. The IVD version of the Idylla™ platform may not be available for sale in other countries worldwide. Please check availability with the local Biocartis sales representative. Idylla™ platform is for Research Use Only and not for use in diagnostic procedures in the US and Canada.
|
| |
| |
|
| |
|
|
|
|
0
/250